Clin Oncol | Volume 4, Issue 1 | Case Report | Open Access

Ulceration of Steroid-Induced Striae Distensae in a Patient with a Rare Brain Tumor on Bevacizumab

Eleni Pilitsi¹, Stephanie Wang², Marylee Braniecki³ and Maria Lina Tsoukas^2*

¹Department of Medicine, Democritus University of Thrace, Greece
²Department of Dermatology, University of Illinois at Chicago, USA
³Department of Pathology, University of Illinois at Chicago, USA

^*Correspondance to: Maria Lina Tsoukas 

Abstract

Bevacizumab, a Vascular Endothelial Growth Factor (VEGF) inhibitor, is approved for recurrent glioblastoma and various metastatic cancers. VEGF plays an important role in angiogenesis and wound healing and thus, the use of Bevacizumab has been associated with dehiscence, ecchymosis, surgical site bleeding, and wound infection. A unique side-effect of Bevacizumab is the ulceration of steroid-induced striae distensae in patients treated for brain tumors, mainly glioblastoma. Here we report for the first time the case of a young female who presented with ulcerated striae while on treatment with Dexamethasone and Bevacizumab for anaplastic hemangiopericytoma, a rare malignancy of the central nervous system.

Citation:

Pilitsi E, Wang S, Braniecki M, Tsoukas ML. Ulceration of Steroid-Induced Striae Distensae in a Patient with a Rare Brain Tumor on Bevacizumab. Clin Oncol. 2019; 4: 1619.